While previous studies have reported similar mechanisms, this study is the first to propose a nanoparticle-based delivery strategy to enhance acetate levels, thereby achieving targeted modulation of the GPR43 signaling axis for HCC prevention and treatment. This evidence concerns the gene FFAR2 and hepatocellular carcinoma.